Cann Group Ltd Total Liabilities

Latest as of December 2025: AU$21.39 Million AUD ≈ $15.13 Million USD

Cann Group Ltd total liabilities. Based on the latest financial reports, Cann Group Ltd (CAN) has total liabilities worth AU$21.39 Million AUD (≈ $15.13 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Cann Group Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Cann Group Ltd (2015–2025)

Total liabilities of Cann Group Ltd from 2015 to 2025. This chart illustrates how Cann Group Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Cann Group Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.

Cann Group Ltd Competitors by Total Liabilities

The table below lists competitors of Cann Group Ltd ranked by their total liabilities.

Company Country Total Liabilities
Identitii Ltd
AU:ID8
Australia AU$1.96 Million
333D Ltd
AU:T3D
Australia AU$385.73K
Macarthur Minerals Ltd
AU:MIO
Australia AU$1.32 Million
Austchina Holdings Ltd
AU:AUH
Australia AU$1.64 Million
ESE Entertainment Inc
V:ESE
Canada CA$9.18 Million
Australasian Metals Ltd
AU:A8G
Australia AU$210.16K
Zonte Metals Inc
V:ZON
Canada CA$1.72 Million
Agri-Tech (India) Limited
NSE:AGRITECH
India Rs10.10 Million

Liability Composition Analysis (2015–2025)

This chart breaks down Cann Group Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Cann Group Ltd (CAN) total assets.

Liquidity & Leverage Metrics

Cann Group Ltd Total Liabilities Ratios Explained

Cann Group Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 0.42 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio 0.05 Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.63 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.39 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Cann Group Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Cann Group Ltd (2015–2025)

The table below shows the annual total liabilities of Cann Group Ltd from 2015 to 2025.

Year Total Liabilities Change
2025-06-30 AU$81.56 Million
≈ $57.71 Million
+3.44%
2024-06-30 AU$78.85 Million
≈ $55.79 Million
+12.31%
2023-06-30 AU$70.20 Million
≈ $49.67 Million
+28.20%
2022-06-30 AU$54.76 Million
≈ $38.75 Million
+452.02%
2021-06-30 AU$9.92 Million
≈ $7.02 Million
-35.28%
2020-06-30 AU$15.33 Million
≈ $10.84 Million
+218.28%
2019-06-30 AU$4.82 Million
≈ $3.41 Million
+419.10%
2018-06-30 AU$927.67K
≈ $656.39K
+124.15%
2017-06-30 AU$413.87K
≈ $292.84K
+159.14%
2016-12-31 AU$159.71K
≈ $113.01K
-12.17%
2016-06-30 AU$181.85K
≈ $128.67K
+133.65%
2015-06-30 AU$77.83K
≈ $55.07K
--

About Cann Group Ltd

AU:CAN Australia Drug Manufacturers - Specialty & Generic
Market Cap
$5.87 Million
AU$8.30 Million AUD
Market Cap Rank
#28531 Global
#1499 in Australia
Share Price
AU$0.01
Change (1 day)
+0.00%
52-Week Range
AU$0.00 - AU$0.01
All Time High
AU$3.98
About

Cann Group Limited, together with its subsidiaries, engages in the breeding, cultivation, manufacture, and sale of medicinal cannabis in Australia and Europe. Its product portfolio includes the Satipharm delivery system for cannabinoids. The company was founded in 2014 and is based in Mildura, Australia.